CDT Equity Expands ATM Offering to $76M, Authorizing Massive Potential Dilution
CDT is trading near its 52-week low of $3.83 (0.8% below the low) on elevated volume (2.4× avg).
Summary
CDT Equity Inc. has significantly expanded its At-The-Market (ATM) equity offering program, increasing the potential sale of common stock from $3.5 million to over $76 million, representing a substantial potential dilution.
Key Events · Financing and Capital Events · CDT
-
ATM Program Dramatically Expanded
The company increased the aggregate amount of common stock that may be offered and sold under its At-The-Market (ATM) program from $3,556,586 to $76,077,218.
-
Significant Potential Dilution
The new authorization allows for the sale of shares representing over 300% of the company's current market capitalization, indicating a substantial potential dilution for existing shareholders.
-
Enabled by Public Float Increase
The expansion was made possible because the company's public float exceeded $75.0 million as of March 24, 2026, removing previous limitations under Form S-3. This follows a recent reverse stock split.
-
Amendment to Existing Program
This is Amendment No. 6 to a prospectus supplement, updating an existing Sales Agreement dated October 23, 2024, with A.G.P./Alliance Global Partners.
Analysis · CDT · Life Sciences
This filing reveals a dramatic increase in CDT Equity Inc.'s At-The-Market (ATM) equity offering program, raising the authorized amount from approximately $3.5 million to over $76 million. This expansion, enabled by the company's public float exceeding $75 million, allows the company to sell shares equivalent to more than three times its current market capitalization. While it provides a significant capital raising facility, the potential for such extensive dilution is highly negative for existing shareholders, especially given the stock is trading near its 52-week low. This move suggests a critical need for capital and will likely exert substantial downward pressure on the stock price as shares are sold into the market. This follows a recent 1-for-25 reverse stock split on March 26, 2026, which likely contributed to the public float increase, enabling this larger offering.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 41.8% of the 507 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.1M. The 52-week trading range was $3.83 to $4,200.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.